Nestle researchers link IBS to anxietyResearchers at Nestlé Research Center in Lausanne and Canadian collaborators have found that the microbiome of irritable bowel syndrome patients affects their susceptibility for anxiety disorders. more ➔
FDA grants Priority Review to avelumab Avelumab, Merck KGaA’s and Pfizer’s Phase III checkpoint inhibitor, has been granted Priority Review from the US Food and Drug Administration in urothelial carcinoma patients who progressed on or after … more ➔
Big Pharma pushing up orphan drug prices The times in which biotechs dominate the orphan drug market are over. A report from business intelligence provider Evaluate Ltd. concludes that only three in ten OD developers are still biotech SME … more ➔
European dynamics in AMRAround 130 antibiotics experts joined the 10th Berlin Conference on 24th February to highlight high dynamics of European AMR activities. more ➔
Oncopeptides raises €68m in IPOSwedish cancer med developer Oncopeptides AB has raised SEK649m (€68m) in an IPO at Nasdaq Stockholm. more ➔
Funding: ENABLE goes pre-clinicalSeveral promising antibiotic candidates, developed by ENABLE and its partners, are rapidly approaching the pre-clinical development stage. The European consortium is now seeking new partners to proceed … more ➔
Kick off for BaseLaunch acceleratorBaseLaunch, a new life sciences accelerator in Basel, has been kicked off. Its mission: to bring the most promising healthcare projects and ventures to Europe’s leading life sciences hub. more ➔
Roche extends antibiotics collaboration While governments worldwide discuss to pay premiums to pharma companies offering novel antibiotics that fight multiresistant pathogens, Roche has extended its discovery deal with British Discuva … more ➔
Bioplastics market growth dropsGrowth of the bioplastics market in the EU is being hampered by lack of political support. According to market analysis from nova-institute, production capacity for bio-based polymers in 2016 dropped … more ➔
Roche combo doubles RCC survival vs suniti...A combination therapy of Roche’s checkpoint inhibitor atezolizumab plus its VEGF blocker bevacizumab doubles median progression-free survival (PFS) compared to sunitinib, the standard care in renal cell … more ➔
